Tag Archives: BIO Investor Forum

BIO Investor Forum Company Snapshot: NovelMed Therapeutics

NovelMed

NovelMed Therapeutics will be presenting at the upcoming BIO Investor Forum in October in San Francisco. Read below to learn more about their antibodies portfolio, what differentiates their company for the competition, and other interesting facts about the company. Company Snapshot What is your company’s lead product or technology? NovelMed has developed a portfolio of fully humanized monoclonal antibodies that selectively target only the disease-associated Complement System. As such, NovelMed’s antibodies are active against multiple Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , ,

GAINing Ground in Antibiotics

GAIN

With the rise of antibiotic resistant “superbugs” in recent years, everyone agrees there is an urgent need to develop new and effective antibiotics. One measure designed to spur such development is the Generating Antibiotics Incentives Now (GAIN) Act, which was enacted last year. The law provides an additional five years of market exclusivity and priority FDA review for innovative antibiotics that target qualifying pathogens. Much of the current research in the field is being done Read More >

Business and Investments, Health  |  Leave a comment  |  Email This Post
Tags: , , ,

BIO Investor Forum Company Snapshot: MAX BioPharma

maxbiopharma

Earlier this week, we featured a presenting company for our upcoming BIO Investor Forum event in San Francisco in our ‘company snapshot‘ feature. For our next post, we spoke to MAX BioPharma, who will be giving a presentation in our Discovery Company presentation track, which features companies in their Seed or Series A financing rounds, with under 25 million raised to date. Read on to learn more about this Discovery Company.   Company Snapshot What Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , ,

BIO Investor Forum Company Snapshot: AM-Pharma

AM Pharma

The BIO Investor Forum will be taking place this October in San Francisco for its 12th annual event. So far this year, the hot topic is, of course, the hot market. Out of all the therapeutic US companies that have had an IPO in 2013, 71% of them have attended the BIO Investor Forum. The program for the event will thus feature two great panels about the recent IPO activity, in addition to other therapeutic workshops Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , ,

The Return of the Biotech IPO

Graph

It isn’t just the volume of IPOs this summer that makes this window a victory for hibernating private biotechs and their VC backers, it’s the details of the offerings in terms of price, performance, and type of biotech making the leap onto the public stage. For the last five years we have not seen average offering prices land above expectations, but 2013 is breaking that trend. Price performance is also impressive, with a number of Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , ,